Cybin to participate in the td cowen 4th annual novel mechanisms in neuropsychiatry summit

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that amir inamdar, cybin's chief medical officer, will participate in a panel discussion at the td cowen 4th annual novel mechanisms in neuropsychiatry summit taking place virtually on september 26, 2024. t.
CYBN Ratings Summary
CYBN Quant Ranking